Monoclonal Antibodies as Anticancer Agents

  • Robert K. Oldham
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)


A major problem with current modalities of cancer treatment has been the lack of specificity of the treatment for the cancer cell. It is well known that the therapeutic/toxic ratio is low for anticancer drugs and for radiation therapy. A major advance in the treatment of cancer could be heralded by the development of a class of agents that have a greater degree of specificity for the tumor cell. The technique of hybridization of an immortal myeloma cell line with an antibody-producing B cell as developed by Kohler and Milstein in the late 1970’s provided a technique by which monoclonal antibodies could be produced in virtually unlimited quantities (1). Since the technique involved the selection of single cells and the clonal expansion of a single hybrid between the antibody-forming cell and the myeloma cell, this technique makes available, for the first time, monoclonal antibodies for use in cancer biology. Since most of the monoclonal antibodies developed against human tumor cells have been made in mice by immunizing the mouse with human tumor cells or extracts thereof, these monoclonals are mouse immunoglobulins and represent the way a mouse cell sees a human tumor cell. While there are many difficulties with respect to using mouse immunoglobulins as therapeutic reagents in man, this technique may provide one route around the problem of immunogenicity of tumors in man. It is possible that the mouse will recognize antigenic determinants on the human tumor cell not recognized by the patient’s own immune system or not recognized well by that immune system. If this turns out to be the case, we will have a mechanism for developing specific monoclonal reagents defining antigenic specificities on the tumor cell which may be unique and cancer specific though nonimmunogenic in the primary host. Therefore, investigations into mouse monoclonal antibody may be important even given the future availability of human-derived monoclonal antibodies and even with the potential toxicities of mouse immunoglobulin reagents.


Chronic Lymphocytic Leukemia Human Tumor Cell Monoclonal Antibody Therapy Animal Tumor Model Antigenic Modulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohler, G., and C. Milstein. 1975. Continuous cultures of fushed cells secreting antibody of predefined specificity. Nature (London) 256: 495.CrossRefGoogle Scholar
  2. 2.
    Foon, K. A., M. I. Bernhard, and R. K. Oldham. 1982. Monoclonal antibody therapy: Assessment by animal tumor models. Biol. Resp. Modif. (in press).Google Scholar
  3. 3.
    Sherwin, S. A., K. A. Foon, and R. K. Oldham. 1983. Animal tumor models for biological response modifier therapy: An approach to the development of monoclonal antibody therapy in humans. In: S. Carter (ed.), Principles of cancer chemotherapy. McGraw Hill, New York (in press)Google Scholar
  4. 4.
    Rosenberg, S. A., and W. D. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25: 323.PubMedCrossRefGoogle Scholar
  5. 5.
    Ritz, J., and S. F. Schlossman. 1982. Utilization of monoclonal antibodies in treatment of leukemia and lymphoma. Blood 59: 1.PubMedGoogle Scholar
  6. 6.
    Sears, H. F., B. Atkinson, J. Mattis, C. Ernest, D. Herlyn, Z. Steplewski, P. Häyry, and H. Koprowski. 1982. Phase-1 clincial trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1: 762.PubMedCrossRefGoogle Scholar
  7. 7.
    Ritz, J., J. M. Pesando, S. E. Sallan, A. Clavell, J. NotisMcConarty, P. Rosenthal, and S. F. Schlossman. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58: 141.PubMedGoogle Scholar
  8. 8.
    Miller, R. A., D. G. Maloney, J. McKillop, and R. Levy. 1981. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 78.PubMedGoogle Scholar
  9. 9.
    Dillman, R. O., D. L. Shawler, R. E. Sobol, H. A. Collins, J. C. Beauregard, S. B. Wornsley, and I. Royston. 1982. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59: 1036.PubMedGoogle Scholar
  10. 10.
    Miller, R. A., and R. Levy. 1981. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2: 226.PubMedCrossRefGoogle Scholar
  11. 11.
    Miller, R. A., D. G. Maloney, E. R. Warnicki, and R. Levy. 1982. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306: 517.PubMedCrossRefGoogle Scholar
  12. 12.
    Nadler, L. M., P. Stashenko, and R. Hardy. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40: 3147.PubMedGoogle Scholar
  13. 13.
    Morgan, A. C., Jr., D. R. Galloway, and R. A. Reisfeld. 1981. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1: 27.PubMedCrossRefGoogle Scholar
  14. 14.
    Hanna, M. G., and L. C. Peters. 1978. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine. Cancer Res. 38: 204.PubMedGoogle Scholar
  15. 15.
    Hanna, M. G., and M. E. Key. 1982. Immunotherapy of metastases enhances subsequent chemotherapy. Science 217: 367.PubMedCrossRefGoogle Scholar
  16. 16.
    Bernhard, M. I., K. A. Foon, G. C. Clarke, W. L. Christensen, L. Hoyer, M. G. Hanna, Jr., and R. K. Oldham. 1982. Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy. I. Characterization of monoclonal antibody and description of antigen (submitted).Google Scholar
  17. 17.
    Key, M. E., M. I. Bernhard, K. A. Foon, R. K. Oldham, and M. G. Hanna. 1982. Guinea pig line 10 hepatocarcinoma model for monoclonal antibody serotherapy. II. In vitro localization of a monoclonal antibody in normal and malignant tissues (submitted).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • Robert K. Oldham
    • 1
  1. 1.Division of Cancer Treatment Biological Response Modifiers Program, Frederick Cancer Research CenterNational Cancer InstituteFrederickUSA

Personalised recommendations